The Patent Finder
US

Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect

US 10,441,641 Term ended
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).

Term ended Jun 7, 2026 · High confidence

Filed Sep 14, 2015 as application 14/852,990 · Granted Oct 15, 2019
Base term, 20 years from filing
Today
20 years from filing
Term ended Jun 7, 2026
2006 2026
Clock starts
Jun 7, 2006
Term ended
Jun 7, 2026
Granted
Oct 15, 2019
base term after the term ends fee events Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,926,991, to Jun 7, 2026. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
21
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 7, 2006, when application 11/447,984, the earliest non-provisional in its chain, was filed (this one was filed Sep 14, 2015)Jun 7, 2026High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 8,926,991)resolves to Jun 7, 2026, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 1 maintenance fees paidterm endedHigh confidence
Computed term endThe steps above, in orderJun 7, 2026High confidence

This family

US 8,926,991In force
Oct 2028
Oct 2028
Application 14/464,740Abandoned
not computed
not computed
Application 14/552,755Abandoned
not computed
not computed
Application 14/555,870Abandoned
not computed
not computed
Application 14/573,659Abandoned
not computed
not computed
Application 14/722,990Abandoned
not computed
not computed
Application 14/753,917Abandoned
not computed
not computed
US 10,441,641this patent
Jun 2026
Jun 2026
8 of 21 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Mar 24, 2016
Reel 38096, frame 402
Botulinum Toxin Research Associates, Inc.Borodic, Gary E.Assignment of Assignor's Interest
Mar 24, 2016
Reel 38249, frame 590
Borodic, Gary e, DRBotulinum Toxin Research Associates, Inc.Assignment of Assignor's Interest
Jun 3, 2016
Reel 38870, frame 160
Botulinum Toxin Research Associates, Inc.Revance Therapeutics, Inc.Assignment of Assignor's Interest
Mar 18, 2022
Reel 59437, frame 654
Revance Therapeutics, Inc.Athyrium Buffalo LPSecurity Interest
Feb 7, 2025
Reel 70153, frame 630
Athyrium Buffalo LPRevance Therapeutics, Inc.Release of Security Interest
Feb 7, 2025
Reel 70153, frame 663
Revance Therapeutics, Inc.; Crown Laboratories, Inc.Hayfin Services LLP, as Administrative AgentSecurity Interest
Feb 7, 2025
Reel 70153, frame 736
Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc.Hayfin Services LLP, as Administrative AgentSecurity Interest
Feb 17, 2025
Reel 70239, frame 739
Revance Therapeutics, Inc.Jpmorgan Chase Bank, N.a.Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited